Publikationen in Zusammenarbeit mit Forschern von Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (28)

2024

  1. Mitochondrial DNA deletions in the cerebrospinal fluid of patients with idiopathic REM sleep behaviour disorder

    eBioMedicine, Vol. 102

2022

  1. Cell-free mitochondrial DNA deletions in idiopathic, but not LRRK2, Parkinson's disease

    Neurobiology of Disease, Vol. 174

  2. Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease

    Movement Disorders, Vol. 37, Núm. 5, pp. 1004-1015

  3. Increased Phospho-AKT in Blood Cells from LRRK2 G2019S Mutation Carriers

    Annals of Neurology, Vol. 92, Núm. 5, pp. 888-894

  4. Serum MicroRNAs Predict Isolated Rapid Eye Movement Sleep Behavior Disorder and Lewy Body Diseases

    Movement Disorders, Vol. 37, Núm. 10, pp. 2086-2098

2021

  1. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome

    Nature Communications, Vol. 12, Núm. 1

  2. Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder

    npj Parkinson's Disease, Vol. 7, Núm. 1

  3. Transcriptome analysis in LRRK2 and idiopathic Parkinson’s disease at different glucose levels

    npj Parkinson's Disease, Vol. 7, Núm. 1

2020

  1. MicroRNA Deregulation in Blood Serum Identifies Multiple System Atrophy Altered Pathways

    Movement Disorders, Vol. 35, Núm. 10, pp. 1873-1879

  2. Peripheral insulin and amylin levels in Parkinson's disease

    Parkinsonism and Related Disorders, Vol. 79, pp. 91-96

  3. Regulatory sites for splicing in human basal ganglia are enriched for disease-relevant information

    Nature Communications, Vol. 11, Núm. 1

2019

  1. Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset

    npj Parkinson's Disease, Vol. 5, Núm. 1

  2. Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson’s disease heritability

    npj Parkinson's Disease, Vol. 5, Núm. 1

  3. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: A cross-sectional analysis from the AB255 Study

    Alzheimer's Research and Therapy, Vol. 11, Núm. 1

  4. The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight

    Movement Disorders, Vol. 34, Núm. 12, pp. 1851-1863

2018

  1. MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients

    Neurobiology of Aging, Vol. 69, pp. 283-291

  2. Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis

    Neuropharmacology, Vol. 141, pp. 181-191

  3. α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain

    Movement Disorders, Vol. 33, Núm. 4, pp. 637-641

2017

  1. A protective personal factor against disability and dependence in the elderly: an ordinal regression analysis with nine geographically-defined samples from Spain

    BMC Geriatrics, Vol. 17, Núm. 1, pp. 1-10

2016

  1. Absence of LRRK2 mutations in a cohort of patients with idiopathic REM sleep behavior disorder

    Neurology, Vol. 86, Núm. 11, pp. 1072-1073